Dataset: A 5’ Sequence of Human HMGB2 Gene for Transcriptional Targeting of Glioblastoma
Achievement of specific tumor cell targeting remains a challenge for glioma gene therapy. We report here the identification and...
Achievement of specific tumor cell targeting remains a challenge for glioma gene therapy. We report here the identification and characterization of a 5’ sequence of human HMGB2 gene for transcriptional targeting to glioblastoma. We performed microarray analysis and found HMGB2 as one of the genes that had a low level of expression in normal human astrocytes, but was significantly up-regulated in glioblastoma cells. Real-time PCR quantification revealed increase in HMBG2 expression level in glioblastoma tissues and cells between 11 to 79 fold over that in normal human brain tissue. With progressive truncation of a 5’-upstream sequence of the HMGB2 gene, we identified a 500-bp fragment that displayed a high transcriptional activity in glioblastoma cells, but a low activity in normal brain cells. Using the sequence to drive the expression of the herpes simplex virus thymidine kinase gene in the context of a baculoviral vector, glioblastoma cells died in the presence of ganciclovir, whereas normal human astrocytes and neurons were not affected. We further confirmed that after intra-tumor injection, the baculoviral vector effectively suppressed the growth of human glioblastoma cells in a mouse xenograft model. Our results suggest that the 5’-upstream sequence of the HMGB2 gene can be used as an efficient, tumor-selective promoter in targeted vectors for glioblastoma gene therapy. U251 cells (n=3) genes level expression were compared to that of normal astrocytes (n=3) to find overexpressed genes in glioblastoma. Highly expressed genes were compared to those found in the litterature. This was selected to clone promoters of highly expressed genes in glioblastomas
- Species:
- human
- Samples:
- 6
- Source:
- E-GEOD-12305
- Updated:
- Dec.12, 2014
- Registered:
- Sep.10, 2014
Sample | BIOSOURCEPROVIDER | PASSAGE | GROWTH MEDIUM |
---|---|---|---|
GSM309429 | Lonza (Basel, Switzerland) | 4 | Astrocyte Basal Medium (ABM™) and the following growth supplements: rhEGF, 0.5 ml; Insulin, 1.25 ml; Ascorbic Acid, 0.5 ml; GA-1000, 0.5 ml, L-Glutamine, 5.0 ml; FBS, 15 ml. |
GSM309429 | Lonza (Basel, Switzerland) | 4 | Astrocyte Basal Medium (ABM™) and the following growth supplements: rhEGF, 0.5 ml; Insulin, 1.25 ml; Ascorbic Acid, 0.5 ml; GA-1000, 0.5 ml, L-Glutamine, 5.0 ml; FBS, 15 ml. |
GSM309429 | Lonza (Basel, Switzerland) | 4 | Astrocyte Basal Medium (ABM™) and the following growth supplements: rhEGF, 0.5 ml; Insulin, 1.25 ml; Ascorbic Acid, 0.5 ml; GA-1000, 0.5 ml, L-Glutamine, 5.0 ml; FBS, 15 ml. |
GSM309433 | Lonza (Basel, Switzerland) | 50 | Dulbecco's Modified Eagle Medium and the following growth supplements: Penicillin/streptomycin, 5.0 ml; L-Glutamine, 5.0 ml; FBS, 15 ml. |
GSM309435 | ATCC | 50 | Dulbecco's Modified Eagle Medium and the following growth supplements: Penicillin/streptomycin, 5.0 ml; L-Glutamine, 5.0 ml; FBS, 15 ml. |
GSM309435 | ATCC | 50 | Dulbecco's Modified Eagle Medium and the following growth supplements: Penicillin/streptomycin, 5.0 ml; L-Glutamine, 5.0 ml; FBS, 15 ml. |